Skip to main content
Top
Published in: Molecular Diagnosis & Therapy 5/2023

09-06-2023 | Lymphoma | Original Research Article

Flow Cytometry of CD5-Positive Hairy Cell Leukemia

Authors: Diana Cenariu, Ioana Rus, Jon Thor Bergthorsson, Ravnit Grewal, Mihai Cenariu, Victor Greiff, Adrian-Bogdan Tigu, Delia Dima, Cristina Selicean, Bobe Petrushev, Mihnea Zdrenghea, Jonathan Fromm, Carmen-Mariana Aanei, Ciprian Tomuleasa

Published in: Molecular Diagnosis & Therapy | Issue 5/2023

Login to get access

Abstract

Background and Objective

Hairy cell leukemia (HCL) is a chronic lymphoproliferative disorder for which diagnosis is typically straightforward, based on bone marrow morphology and flow cytometry (FC) or immunohistochemistry. Nevertheless, variants present atypical expressions of cell surface markers, as is the case of CD5, for which the differential diagnosis can be more difficult. The aim of the current paper was to describe diagnosis of HCL with atypical CD5 expression, with an emphasis on FC.

Methods

The detailed diagnostic methodology for HCL with atypical CD5 expression is presented, including differential diagnosis from other lymphoproliferative diseases with similar pathologic features, by FC analysis of the bone marrow aspirate.

Results

Diagnosis of HCL by means of FC started by gating all events based on side scatter (SSC) versus CD45 and B lymphocytes were selected from the lymphocytes gate as CD45/CD19 positive. The gated cells were positive for CD25, CD11c, CD20, and CD103, while CD10 proved to be dim to negative. Moreover, cells positive for CD3, CD4, and CD8, the three pan-T markers, as well as CD19, showed a bright expression of CD5. The atypical CD5 expression is usually correlated with a negative prognosis and thus chemotherapy with cladribine should be initiated.

Conclusion

HCL is an indolent chronic lymphoproliferative disorder and diagnosis is usually straightforward. However, atypical expression of CD5 renders its differential diagnosis more difficult, but FC is a useful tool that allows an optimal classification of the disease and allows initiation of timely satisfactory therapy.
Literature
1.
go back to reference Jasionowski TM, Hartung L, Greenwood JH, Perkins SL, Bahler DW. Analysis of CD10+ hairy cell leukemia. Am J Clin Pat. 2003;120(2):228–35.CrossRef Jasionowski TM, Hartung L, Greenwood JH, Perkins SL, Bahler DW. Analysis of CD10+ hairy cell leukemia. Am J Clin Pat. 2003;120(2):228–35.CrossRef
2.
go back to reference Boyd SD, Natkunam Y, Allen JR, Warnke RA. Selective immunophenotyping for diagnosis of B-cell neoplasms: immunohistochemistry and flow cytometry strategies and results. Appl Immunohistochem Mol Morphol. 2013;21(2):116–31.CrossRefPubMedPubMedCentral Boyd SD, Natkunam Y, Allen JR, Warnke RA. Selective immunophenotyping for diagnosis of B-cell neoplasms: immunohistochemistry and flow cytometry strategies and results. Appl Immunohistochem Mol Morphol. 2013;21(2):116–31.CrossRefPubMedPubMedCentral
3.
4.
go back to reference Isaacs A, Lindenmann J. Virus interference: I. The interferon. CA Cancer J Clin. 1988;38(5):280–90.CrossRef Isaacs A, Lindenmann J. Virus interference: I. The interferon. CA Cancer J Clin. 1988;38(5):280–90.CrossRef
5.
go back to reference Dearden CE, Else M, Catovsky D. Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. Leuk Lymphoma. 2011;52(Suppl 2):21–4.CrossRefPubMed Dearden CE, Else M, Catovsky D. Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. Leuk Lymphoma. 2011;52(Suppl 2):21–4.CrossRefPubMed
7.
go back to reference Maitre E, Cornet E, Troussard X. Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94(12):1413–22.CrossRefPubMed Maitre E, Cornet E, Troussard X. Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94(12):1413–22.CrossRefPubMed
8.
go back to reference Stetler-Stevenson M, Tembhare PR. Diagnosis of hairy cell leukemia by flow cytometry. Leuk Lymphoma. 2011;52(Suppl 2):11–3.CrossRefPubMed Stetler-Stevenson M, Tembhare PR. Diagnosis of hairy cell leukemia by flow cytometry. Leuk Lymphoma. 2011;52(Suppl 2):11–3.CrossRefPubMed
9.
go back to reference Poret N, Fu Q, Guihard S, et al. CD38 in hairy cell leukemia is a marker of poor prognosis and a new target for therapy. Can Res. 2015;75(18):3902–11.CrossRef Poret N, Fu Q, Guihard S, et al. CD38 in hairy cell leukemia is a marker of poor prognosis and a new target for therapy. Can Res. 2015;75(18):3902–11.CrossRef
10.
11.
go back to reference Tallman MS. Clinical features and diagnosis of hairy cell leukemia, UpToDate, 2023. Tallman MS. Clinical features and diagnosis of hairy cell leukemia, UpToDate, 2023.
12.
go back to reference Maitre E, Cornet E, Salaün V, Kerneves P, Chèze S, Repesse Y, Damaj G, Troussard X. Immunophenotypic analysis of hairy cell leukemia (HCL) and hairy cell leukemia-like (HCL-like) disorders. Cancers. 2022;14:1050.CrossRefPubMedPubMedCentral Maitre E, Cornet E, Salaün V, Kerneves P, Chèze S, Repesse Y, Damaj G, Troussard X. Immunophenotypic analysis of hairy cell leukemia (HCL) and hairy cell leukemia-like (HCL-like) disorders. Cancers. 2022;14:1050.CrossRefPubMedPubMedCentral
13.
go back to reference Böttcher S, Engelmann R, Grigore G, Fernandez PC, Caetano J, Flores-Montero J, Van der Velden VHJ, Novakova M, Philippé J, Ritgen M. Expert-independent classification of mature B-cell neoplasms using standardized flow cytometry: a multicentric study. Blood Adv. 2022;6:976–92.CrossRefPubMedPubMedCentral Böttcher S, Engelmann R, Grigore G, Fernandez PC, Caetano J, Flores-Montero J, Van der Velden VHJ, Novakova M, Philippé J, Ritgen M. Expert-independent classification of mature B-cell neoplasms using standardized flow cytometry: a multicentric study. Blood Adv. 2022;6:976–92.CrossRefPubMedPubMedCentral
14.
go back to reference Xi L, Arons E, Navarro W, Calvo KR, Stetler-Stevenson M, Raffeld M, Kreitman RJ. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood. 2012;119(14):3330–2.CrossRefPubMedPubMedCentral Xi L, Arons E, Navarro W, Calvo KR, Stetler-Stevenson M, Raffeld M, Kreitman RJ. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood. 2012;119(14):3330–2.CrossRefPubMedPubMedCentral
15.
go back to reference Javidiparsijani S, Choi YK, Arbini AA. A case of CD5 positive hairy cell leukemia with BRAF V600E mutation and lymph node involvement; unique case report and review of the literature. Blood. 2020;136(Supplement 1):17–8.CrossRef Javidiparsijani S, Choi YK, Arbini AA. A case of CD5 positive hairy cell leukemia with BRAF V600E mutation and lymph node involvement; unique case report and review of the literature. Blood. 2020;136(Supplement 1):17–8.CrossRef
16.
go back to reference Hallek M, Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021;96(12):1679–705.CrossRefPubMed Hallek M, Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021;96(12):1679–705.CrossRefPubMed
17.
go back to reference Soong D, Kumar P, Jatwani K, Park J, Dogan A, Taylor J. Hairy cell leukemia masquerading as CD5+ lymphoproliferative disease: the importance of BRAF V600E testing in diagnosis and treatment. JCO Prec Oncol. 2021;5:1035–9.CrossRef Soong D, Kumar P, Jatwani K, Park J, Dogan A, Taylor J. Hairy cell leukemia masquerading as CD5+ lymphoproliferative disease: the importance of BRAF V600E testing in diagnosis and treatment. JCO Prec Oncol. 2021;5:1035–9.CrossRef
18.
go back to reference Salem DA, Scott D, McCoy CS, Liewehr DJ, Venzon DJ, Arons E, Kreitman RJ, Stetler-Stevenson M, Yuan CM. Differential expression of CD43, CD81, and CD200 in classic versus variant hairy cell leukemia. Cytom Part B. 2019;96B:275–82.CrossRef Salem DA, Scott D, McCoy CS, Liewehr DJ, Venzon DJ, Arons E, Kreitman RJ, Stetler-Stevenson M, Yuan CM. Differential expression of CD43, CD81, and CD200 in classic versus variant hairy cell leukemia. Cytom Part B. 2019;96B:275–82.CrossRef
19.
go back to reference Szczepański T, van der Velden VH, van Dongen JJ. Flow-cytometric immunophenotyping of normal and malignant lymphocytes. Clin Chem Lab Med. 2006;44(7):775–96.CrossRefPubMed Szczepański T, van der Velden VH, van Dongen JJ. Flow-cytometric immunophenotyping of normal and malignant lymphocytes. Clin Chem Lab Med. 2006;44(7):775–96.CrossRefPubMed
20.
go back to reference Shao H, Calvo KR, Grönborg M, Tembhare PR, Kreitman RJ, Stetler-Stevenson M, Yuan CM. Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria. Leuk Res. 2013;37(4):401–9.CrossRefPubMedPubMedCentral Shao H, Calvo KR, Grönborg M, Tembhare PR, Kreitman RJ, Stetler-Stevenson M, Yuan CM. Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria. Leuk Res. 2013;37(4):401–9.CrossRefPubMedPubMedCentral
21.
go back to reference Vittoria L, Bozzi F, Capone I, Carniti C, Lorenzini D, Gobbo M, Bolli N, Aiello A. A rare biclonal Hairy Cell Leukemia disclosed by an integrated diagnostic approach: a case report. Cytom B Clin Cytom. 2021;100(6):692–4.CrossRef Vittoria L, Bozzi F, Capone I, Carniti C, Lorenzini D, Gobbo M, Bolli N, Aiello A. A rare biclonal Hairy Cell Leukemia disclosed by an integrated diagnostic approach: a case report. Cytom B Clin Cytom. 2021;100(6):692–4.CrossRef
22.
go back to reference Mahdi T, Rajab A, Padmore R, Porwit A. Characteristics of lymphoproliferative disorders with more than one aberrant cell population as detected by 10-color flow cytometry. Cytom B Clin Cytom. 2018;94(2):230–8.CrossRef Mahdi T, Rajab A, Padmore R, Porwit A. Characteristics of lymphoproliferative disorders with more than one aberrant cell population as detected by 10-color flow cytometry. Cytom B Clin Cytom. 2018;94(2):230–8.CrossRef
23.
go back to reference Maitre E, Cornet E, Salaün V, Kerneves P, Chèze S, Repesse Y, Damaj G, Troussard X. Immunophenotypic analysis of hairy cell leukemia (HCL) and hairy cell leukemia-like (HCL-like) disorders. Cancers (Basel). 2022;14(4):1050.CrossRefPubMedPubMedCentral Maitre E, Cornet E, Salaün V, Kerneves P, Chèze S, Repesse Y, Damaj G, Troussard X. Immunophenotypic analysis of hairy cell leukemia (HCL) and hairy cell leukemia-like (HCL-like) disorders. Cancers (Basel). 2022;14(4):1050.CrossRefPubMedPubMedCentral
24.
go back to reference Robak T. Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment. Cancer Treat Rev. 2011;37(1):3–10.CrossRefPubMed Robak T. Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment. Cancer Treat Rev. 2011;37(1):3–10.CrossRefPubMed
25.
go back to reference Venkataraman G, Aguhar C, Kreitman RJ, Yuan CM, Stetler-Stevenson M. Characteristic CD103 and CD123 expression pattern defines hairy cell leukemia: usefulness of CD123 and CD103 in the diagnosis of mature B-cell lymphoproliferative disorders. Am J Clin Pathol. 2011;136(4):625–30.CrossRefPubMed Venkataraman G, Aguhar C, Kreitman RJ, Yuan CM, Stetler-Stevenson M. Characteristic CD103 and CD123 expression pattern defines hairy cell leukemia: usefulness of CD123 and CD103 in the diagnosis of mature B-cell lymphoproliferative disorders. Am J Clin Pathol. 2011;136(4):625–30.CrossRefPubMed
26.
go back to reference Cessna MH, Hartung L, Tripp S, Perkins SL, Bahler DW. Hairy cell leukemia variant: fact or fiction. Am J Clin Pathol. 2005;123(1):132–8.CrossRefPubMed Cessna MH, Hartung L, Tripp S, Perkins SL, Bahler DW. Hairy cell leukemia variant: fact or fiction. Am J Clin Pathol. 2005;123(1):132–8.CrossRefPubMed
Metadata
Title
Flow Cytometry of CD5-Positive Hairy Cell Leukemia
Authors
Diana Cenariu
Ioana Rus
Jon Thor Bergthorsson
Ravnit Grewal
Mihai Cenariu
Victor Greiff
Adrian-Bogdan Tigu
Delia Dima
Cristina Selicean
Bobe Petrushev
Mihnea Zdrenghea
Jonathan Fromm
Carmen-Mariana Aanei
Ciprian Tomuleasa
Publication date
09-06-2023
Publisher
Springer International Publishing
Keywords
Lymphoma
Leukemia
Published in
Molecular Diagnosis & Therapy / Issue 5/2023
Print ISSN: 1177-1062
Electronic ISSN: 1179-2000
DOI
https://doi.org/10.1007/s40291-023-00658-x

Other articles of this Issue 5/2023

Molecular Diagnosis & Therapy 5/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine